TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05093192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise trial
Description: Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise trial
Description: Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise trial
Description: Participants will perform a supervised acute bout of aerobic exercise over 20-30 minutes, corresponding to a target power output at an intensity +10 to 15% above ventilatory threshold.
Study: NCT04274517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.05% Chlorhexidine Gluconate
Description: 1L of clorhexidine gluconate used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
Study: NCT06003595

Intervention type: OTHER
Intervention: Data collection on patient reported long-term outcome of SSRF hardware removal
Description: One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
Study: NCT05761691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Children treated for ECC under general (DGA) and local anesthesia (LA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Children treated for ECC under general (DGA) and local anesthesia (LA).
Study: NCT06300021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG capsule
Description: A dietary supplement product in capsule form containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG capsule
Description: A dietary supplement product in capsule form containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG capsule
Description: A dietary supplement product in capsule form containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG capsule
Description: A dietary supplement product in capsule form containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG capsule
Description: A dietary supplement product in capsule form containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG capsule
Description: A dietary supplement product in capsule form containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG ready to drink
Description: Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG ready to drink
Description: Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG ready to drink
Description: Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG ready to drink
Description: Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar
Study: NCT06564246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan 20 mg versus Pantoprazole 40 mg
Description: Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan 20 mg versus Pantoprazole 40 mg
Description: Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
Study: NCT04839289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument; Manufacturer A
Description: Commercially available receiver-in-canal hearing instrument from manufacturer A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument; Manufacturer A
Description: Commercially available receiver-in-canal hearing instrument from manufacturer A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument; Manufacturer B
Description: Commercially available receiver-in-canal hearing instrument from manufacturer B

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument; Manufacturer B
Description: Commercially available receiver-in-canal hearing instrument from manufacturer B
Study: NCT05776745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech
Description: Patients read specific words and sentences

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereoelectroencephalography
Description: Using stereoelectroencephalography to record the Intracranial EEG of the patient
Study: NCT05561387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC
Study: NCT06539065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR interactive games
Description: The experimental group received a twelve-week intervention of 36 sessions using VR interactive games in their exercise prescription,
Study: NCT06300021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG sport bar
Description: Sport nutrition bar containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG sport bar
Description: Sport nutrition bar containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG sport bar
Description: Sport nutrition bar containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG sport bar
Description: Sport nutrition bar containing 300 mg Turmipure Gold®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG sport bar
Description: Sport nutrition bar containing 300 mg Turmipure Gold®
Study: NCT05013255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15mg
Description: PIO 15mg orally once daily for 2 weeks
Study: NCT06300021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPG sport bar
Description: Sport nutrition bar containing 300 mg Turmipure Gold®
Study: NCT05013255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: PIO 30mg orally once daily for 2 weeks
Study: NCT06480383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 10 mg
Description: ITI-1284 10 mg tablet, taken once daily, sublingual administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284 20 mg
Description: ITI-1284 20 mg tablet, taken once daily, sublingual administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet, taken once daily, sublingual administration
Study: NCT06585202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2138
Description: ATI-2138 Oral Tablets BID
Study: NCT05933499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV bimagrumab
Description: IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: IV placebo (administered at 0, 4, 16, 28, and 40 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV placebo
Description: IV placebo (administered at 0, 4, 16, 28, and 40 weeks)
Study: NCT06531720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: topical preparation applied on oral mucosa lesion containing 0,2% CHX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Salicylate 8.7 % Oral Gel
Description: topical preparation applied on oral mucosa lesion containing, ethanol-based

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: no medication has been prescribed
Study: NCT05933499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide 2.4mg SQ qweek

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium/Vitamin D
Description: Elemental calcium 1200 mg + vitamin D3 800 IU PO daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Elemental calcium 1200 mg + vitamin D3 800 IU PO daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Elemental calcium 1200 mg + vitamin D3 800 IU PO daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle and nutrition counseling
Description: Lifestyle and nutrition counseling consistent with current guidelines for weight management

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle and nutrition counseling
Description: Lifestyle and nutrition counseling consistent with current guidelines for weight management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and nutrition counseling
Description: Lifestyle and nutrition counseling consistent with current guidelines for weight management
Study: NCT06535529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
Study: NCT04744363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stelara PFS
Description: Pre filled syringes filled with AVT04 and Stelara

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara PFS
Description: Pre filled syringes filled with AVT04 and Stelara

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara PFS
Description: Pre filled syringes filled with AVT04 and Stelara
Study: NCT05526443

Intervention type: DRUG
Intervention: all approved chemotherapeutic agents from second line
Description: all approved chemotherapeutic agents from second line
Study: NCT06544473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-beta estradiol
Description: Treatment with orally administered estrogen for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-beta estradiol
Description: Treatment with transdermally administered estrogen for 14 days
Study: NCT06540157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural Beat Music (BBM) Combined with Rhythmic Photic Stimulation (RPS)
Description: Participants rested on a chair for 10 minutes before the intervention. Participants wore over-ear stereo headphones and RPS glasses, receiving 20 minutes of 10Hz BBM (embedded with classic old songs as mask music) and RPS. The BBM and RPS glasses were purchased from George Szeless's mindLightz.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: Participants rested on a chair for 10 minutes before the intervention. Participants wore the same headphones and RPS glasses as the BBM and RPS group but listened to classic Taiwanese old songs without the 10Hz light stimulation from the RPS glasses.
Study: NCT06232538

Intervention type: DIAGNOSTIC_TEST
Intervention: The level of CNV
Description: The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
Study: NCT05164510

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ct-DNA guided therapy
Description: treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
Study: NCT05418621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative application
Description: in the test group, EMD (Emdogain FL®, Institute Straumann AG, Basel, Switzerland) will be applied with a dedicated syringe until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline application
Description: in the control group, a lavage of sterile saline will be applied with a syringe with a thin blunt tip until overflowing from the pocket border, taking particular care in avoiding trauma to the tissues.
Study: NCT04892654

Intervention type: DRUG
Group type: OTHER
Intervention: Doravirine
Description: Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir
Description: Antiretroviral, Integrase strand transfer inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Antiretroviral, Integrase strand transfer inhibitors
Study: NCT05430009

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Liver SBRT
Description: 24-45 Gy delivered in 3-5 fractions to 1-4 lesions.
Study: NCT04892654

Intervention type: OTHER
Group type: OTHER
Intervention: Triple cART regimen
Description: Participant standard triple cART regimen
Study: NCT05430009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg every 3 weeks or 400 mg every 6 weeks
Study: NCT06613542

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4g of taurine daily
Description: Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months
Study: NCT05907902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: low-dose aspirin 100 mg once daily (one 100mg tablet).
Study: NCT05763277

Intervention type: DIAGNOSTIC_TEST
Intervention: Early response evaluation
Description: Atezolizumab and bevacizumab are administered every three weeks, and before to the second treatment cycle, blood tests and imaging tests are conducted (week 5). This precedes the standard response evaluation (week 9-12).
Study: NCT05739227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allogenic CD19-CAR-NK cells
Description: The relapsed/refractory B-cell hematologic malignancies patients will receive allogenic CD19-Targeted CAR-NK cells infusion up to 3 dose levels (1x10\^6/kg, 5x10\^6/kg, 2x10\^7/kg) after FCE chemotherapy
Study: NCT06045832

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAXPOWER Biological Antibacterial Liquid
Description: MAXPOWER Biological Antibacterial Liquid is a mouthwash product self-developed in China, which contains betaine, antibacterial peptide and other antimicrobial substances, which have been proved by experiments to have a good biological safety and at the same time have a killing effect on bacteria. Mouthwash belongs to the category of medical devices, not drugs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water
Study: NCT04923386

Intervention type: OTHER
Intervention: None (not interventional)
Description: This is not an intervention
Study: NCT04883411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
Description: Two-Level ACDF with CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
Study: NCT05766761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention condition, the usual prenatal care plus the alcohol intervention
Description: The intervention is theory-driven, based on Motivational Enhancement Theory (MET), and uses motivational strategies to promote alcohol reduction.
Study: NCT05931952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Description: Group A: Buteyko breathing technique and conventional (chest physiotherapy) treatment for 5 times a week for about 20 minutes in one session for a period of 4 weeks. There are three steps involved in buteyko breathing technique.~Step 1; control pause breathing test (patient is asked to sit in an upright position and take normal breath. After this, asked the patient to take small breath-in for 2s and out for 3s. Control pause phase should not exceed for \>30 seconds).~Step 2; maximum pause or shallow breathing (patient is asked to place fingers under the nose to monitor inflow of air. 2 or 3 flickers of air is taken in and exhale as slowly as possible).~Step 3; combine step 1 and 2. Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papworth method
Description: Papworth method and conventional chest physiotherapy (bronchial drainage) treatment. Intervention will be given for a period of 5 sessions per week for 1 month. Duration of each session will be 20 minutes. This technique is performed particularly during remission period that make it feasible for respiratory physiotherapist to integrate this method into activities of daily living. Papworth method has five components including Papworth method ameliorates asthmatic symptoms breathing, education, relaxation, combination of breathing and relaxation exercise and home exercises and also improves quality of life.~Bronchial drainage will be performed as a conventional treatment for 2 to 3 minutes in each segment. During that time, patient is asked to take deep and slow breaths followed by cough to help in clearing mucus.
Study: NCT05524207

Intervention type: PROCEDURE
Intervention: carotid artery stenting
Description: Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis

Intervention type: PROCEDURE
Intervention: carotid artery stenting
Description: Implantation of stents at the site of carotid artery stenosis for the treatment of carotid plaque with severe stenosis
Study: NCT05066607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Patient will receive the association of Isatuximab, Pomalidomide and Dexamethasone during 9 or 12 cycles.
Study: NCT05567094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Patients will receive 2ml saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Study: NCT05561387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study: NCT06537908

Intervention type: DRUG
Intervention: Anti-PD-1/PD-L1 antibodies
Description: Anti-PD-1/PD-L1 Intravenous injection for at least 6 months

Intervention type: DRUG
Intervention: Anti-VEGF
Description: Anti-VEGF Intravenous injection for at least 6 months
Study: NCT05672173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and/or aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lisocabtagene Maraleucel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05020483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEIBA
Description: Administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously. Three small doses, 5 mg/kg each, will be available.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active ingredient and administered via the central line catheter after termination of cardiopulmonary bypass if bleeding related to poor clotting develops; in addition, according to conventional protocol blood products will be transfused simultaneously.
Study: NCT05954897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
Description: RALOX Regimen of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Tislelizumab
Study: NCT05672173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05184413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Description: A multimodal telerehabilitation intervention will be conducted through Whatsapp video calls. The combined treatment includes: 1) One 30-minute session of education in neurosciences of pain, using audiovisual material with examples and metaphors to improve the patient's understanding. In addition, two sessions of reinforcement of key contents will be held every 15 days; 2) Therapeutic exercise program: active wrist and finger exercises, stretching, mobilization exercises of the median nerve, and aerobic exercise (brisk walking). Each exercise will be dosed on a personalized basis, with a perceived exertion of 4-5 on the Borg scale. Therapeutic exercise will be self-administered, 3 sessions per week for 6 weeks. Telerehabilitation sessions will be performed every 15 days to monitor adherence and adjust the exercise dose.
Study: NCT05561387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO